Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Next-Generation Sequencing in Medicine (Upcoming)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer
Sabina Signoretti, … , Massimo Loda, Michele Pagano
Sabina Signoretti, … , Massimo Loda, Michele Pagano
Published September 1, 2002
Citation Information: J Clin Invest. 2002;110(5):633-641. https://doi.org/10.1172/JCI15795.
View: Text | PDF | Retraction
Article Oncology

Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer

  • Text
  • PDF
Abstract

Research Article

Authors

Sabina Signoretti, Lucia Di Marcotullio, Andrea Richardson, Sridhar Ramaswamy, Beth Isaac, Montserrat Rue, Franco Monti, Massimo Loda, Michele Pagano

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Hierarchical clustering of 89 breast tumor samples (sample set A). Each ...
Hierarchical clustering of 89 breast tumor samples (sample set A). Each column represents a tumor sample, and each row represents a different gene probe set. The relative expression level of the genes in the samples is indicated by a gradient of color, with blue representing expression levels below the mean and red representing expression levels above the mean. The tumors are clustered in the dendrogram at the top, and the genes are clustered in the dendrogram down the side. Tumors and genes appearing next to each other are more similar in expression pattern. The pathologic data for each tumor sample is represented by the color bars below the tumor dendrograms: dark blue, modified Bloom-Richardson grade III; light blue, modified Bloom-Richardson grade I or II; dark green, ER and PR positive; light green, ER and PR negative; dark purple, Her-2 overexpressed (3+); light purple, Her-2 nonoverexpressed. The tumor clusters showing the highest levels of Skp2 expression and the gene clusters that include the Skp2 gene are highlighted in orange. (a) Hierarchical clustering of 89 tumors for 2,130 filtered genes. (b) Clustering of 89 tumors to demonstrate relative expression of 41 selected genes, including cell cycle regulatory genes (e.g., cyclins, Cdks, Cks1, Cks2, PCNA, p16), keratins, hormone receptors (e.g., ERα, ERβ, ERRα, androgen receptor), ER-associated genes (e.g., HNF3, TFF3, GATA3, LIV-1), Her-2 amplicon genes (e.g., Her-2, PPAR-binding protein, MLN64, GRB7), and genes associated with the basal-like tumor subgroup (e.g., UDP-N-Ac-galactosamine, chitinase 3-like 2, P-cadherin, AC133/prominin-like 1, HDGF).

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts